MCL Literature Feed

154 papers on mantle cell lymphoma from PubMed. Updated daily.

ADC BCL2i BTKi CAR-T CDK4/6i CNS MRD PI3Ki TP53-mutated biomarkers bispecific blastoid case report chemotherapy consolidation elderly epidemiology frontline genomics guidelines

ROR1-AS1: A Meaningful Long Noncoding RNA in Oncogenesis.

This review identifies the lncRNA ROR1-AS1 as a pro-oncogenic factor in mantle cell lymphoma, suggesting it may serve as a novel biomarker or therapeutic target.

Hong Fan, Yunxi Zhou, Ziyan Zhang et al.·Mini reviews in medicinal chemistry·Jan 1, 2024

review preclinical biomarkers genomics

Chimeric antigen receptor T-cell therapy for aggressive B-cell lymphomas.

This review consolidates efficacy and toxicity data for FDA-approved CAR-T products in aggressive B-cell lymphomas, including MCL, serving as a practical guide for this established relapsed/refractory treatment.

Bei Hu, Victoria Korsos, M Lia Palomba·Frontiers in oncology·Jan 1, 2024

CAR-T relapsed/refractory review toxicity

Emerging Role of Functional Magnetic Resonance Spectroscopy (MRS) to Monitor Response to Kinase Inhibitors in Cancer.

Magnetic Resonance Spectroscopy (MRS) can non-invasively detect metabolic changes, like lactate and alanine, offering an early biomarker to predict response or resistance to BTK inhibitors in MCL.

Kavindra Nath, Pradeep K Gupta, Mariusz A Wasik·Advances in cancer research & clinical imaging : ACRCI·Jan 1, 2024

BTKi preclinical review biomarkers resistance

[Update on treatment strategies for mantle cell lymphoma].

This review summarizes the evolving Japanese MCL treatment landscape, highlighting novel therapies like BTKi, BCL2i, and CAR-T to address resistance in high-risk subsets like TP53-mutated and blastoid.

Suguru Fukuhara·[Rinsho ketsueki] The Japanese journal of clinical hematology·Jan 1, 2024

BTKi BCL2i CAR-T transplant TP53-mutated blastoid review resistance

← PreviousPage 6 of 6